Mira Pharmaceuticals Appoints New Chief Medical Officer
Ticker: MIRA · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
Mira Pharma names Dr. Cohen as new CMO, effective March 7th.
AI Summary
Mira Pharmaceuticals, Inc. announced on March 13, 2024, that its Board of Directors appointed Dr. Jonathan L. Cohen as Chief Medical Officer, effective March 7, 2024. Dr. Cohen brings extensive experience in drug development and clinical research to the role. This appointment is part of the company's ongoing efforts to advance its pharmaceutical pipeline.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's drug development strategy and clinical trial progress.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially a CMO, can signal shifts in strategy or operational focus, carrying inherent risks until their impact is clear.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Newly appointed Chief Medical Officer
- March 13, 2024 (date) — Date of Report
- March 7, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan L. Cohen has been appointed as the new Chief Medical Officer.
When was Dr. Jonathan L. Cohen's appointment effective?
Dr. Jonathan L. Cohen's appointment was effective March 7, 2024.
What is the name of the company filing this report?
The company filing this report is Mira Pharmaceuticals, Inc.
What is the date of the report?
The date of the report is March 13, 2024.
What is the primary business of Mira Pharmaceuticals, Inc. according to the filing?
Mira Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 1,463 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2024-03-13 16:30:34
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 46KB
- 0001493152-24-009829.txt ( ) — 220KB
- mira-20240313.xsd (EX-101.SCH) — 3KB
- mira-20240313_lab.xml (EX-101.LAB) — 33KB
- mira-20240313_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Date: March 13, 2024 By: /s/ Michelle Yanez Michelle Yanez Chief Financial Officer